TrialCancer medicine2020

First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.

Karim Amrane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.